Evidence map›Paper›PMID 39886503›Full record

ArticleBMJ oncology2023

Use of immunosuppression and subsequent cancer incidence: cohort study.

Jeanine M Buchanich, Craig W Newcomb, Terri L Washington, Charles Stephen Foster, Lucia Sobrin, Jennifer E Thorne, Douglas Alan Jabs, Eric B Suhler, James T Rosenbaum, Hatice Nida Sen and 27 more

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMJ oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00116090 (Systemic Immunosupressive Therapy for Eye Diseases), which is not on this map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00116090 completednot on this map

Systemic Immunosupressive Therapy for Eye Diseases (SITE) Cohort Study

TypeobservationalSponsorNational Eye Institute (NEI)Ran2005 to 2008Enrolled6,300ConditionsUveitis, Cancer, Infection, Mortality
3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Cancer in connective tissue disease.Frontiers in immunology · 2025
    Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

37 authors.

Jeanine M BuchanichDepartment of Biostatistics, University of Pittsburgh School of Public Health, Pittsburgh, Pennsylvania, USA.
Craig W NewcombCenter for Clinical Epidemiology and Biostatistics, Department of Biostatistics and Epidemiology, The Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Terri L WashingtonDepartment of Biostatistics, University of Pittsburgh School of Public Health, Pittsburgh, Pennsylvania, USA.
Charles Stephen FosterMassachusetts Eye Research and Surgery Institution, Boston, Massachusetts, USA.
Lucia SobrinDepartment of Ophthalmology, Massachusetts Eye and Ear, Boston, Massachusetts, USA.
Jennifer E ThorneWilmer Eye Institute, Department of Ophthalmology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Douglas Alan JabsWilmer Eye Institute, Department of Ophthalmology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Eric B SuhlerDepartment of Ophthalmology, Oregon Health & Science University, Portland, Oregon, USA.
James T RosenbaumDepartment of Ophthalmology, Oregon Health & Science University, Portland, Oregon, USA.
Hatice Nida SenDepartment of Ophthalmology, The George Washington University School of Medicine and Health Sciences, Washington, District of Columbia, USA.
Grace A Levy-ClarkeDepartment of Ophthalmology and Visual Sciences, West Virginia University School of Medicine, Morgantown, West Virginia, USA.
Robert B NussenblattLaboratory of Immunology, National Eye Institute, Bethesda, Maryland, USA.
Nirali P BhattDepartment of Ophthalmology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA.
Careen Y LowderCole Eye Institute, Department of Ophthalmology, Cleveland Clinic, Cleveland, Ohio, USA.
Debra A GoldsteinDepartment of Ophthalmology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
Yannek I LeidermanIllinois Eye & Ear Infirmary, Department of Ophthalmology and Visual Sciences, University of Illinois Chicago College of Medicine, Chicago, Illinois, USA.
Nisha R AcharyaF.I. Proctor Foundation, University of California San Francisco, San Francisco, California, USA.
Gary N HollandOcular Inflammatory Disease Center, Jules Stein Eye Institute, Department of Ophthalmology, David Geffen School of Medicine, Los Angeles, California, USA.
Russell W ReadDepartment of Ophthalmology and Visual Sciences, The University of Alabama at Birmingham Heersink School of Medicine, Birmingham, Alabama, USA.
James P DunnMid-Atlantic Retina, Wills Eye Hospital, Philadelphia, Pennsylvania, USA.
Kurt A DregerDepartment of Population, Family, and Reproductive Health, Johns Hopkins University, Baltimore, Maryland, USA.
Pichaporn ArtornsombudhDepartment of Ophthalmology, Somdech Phra Pinkloa Hospital, Royal Thai Navy, Bangkok, Thailand.
Hosne A BegumWilmer Eye Institute, Department of Ophthalmology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Tonetta D FitzgeraldDepartment of Ophthalmology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA.
Srishti KothariDepartment of Ophthalmology and Schepens Eye Research Institute, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, Massachusetts, USA.
Abhishek R PayalMahatme EyeBank Eye Hospital, Nagpur, Maharashtra, India.
Ebenezer DanielDepartment of Ophthalmology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA.
Sapna S GangaputraVanderbilt Eye Institute, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Roje Oktay KaçmazSanten Pharmaceutical Co Ltd, Emeryville, California, USA.
Teresa L LiesegangDepartment of Ophthalmology, Oregon Health & Science University, Portland, Oregon, USA.
Siddharth S PujariSiddharth Netralaya Superspecialty Eye Hospital, Belgaum, Karnataka, India.
Naira KhachatryanDepartment of Ophthalmology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA.
Armin MaghsoudlouNeurology, Northwell Health, Staten Island, New York, USA.
Hilkiah K SugaMyungSung Medical College, Addis Ababa, Addis Ababa, Ethiopia.
Clara M PakMCM Eye Unit, MyungSung Christian Medical Center (MCM) General Hospital and MyungSung Medical School, Addis Ababa, Addis Ababa, Ethiopia.
Kathy J HelzlsouerDepartment of Epidemiology, The Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.
John H KempenDepartment of Ophthalmology, Massachusetts Eye and Ear, Boston, Massachusetts, USA.ORCID 0000-0002-2967-4792

Funding

Long-term Follow-up of the Systemic Immunosuppressive Therapy for Eye Diseases CohortR01EY014943 · NEI · UNIVERSITY OF PENNSYLVANIA · PI KEMPEN, JOHN H · 2004 to 2025
$8.1M
Incidence of remission and of cataract in ocular inflammatory diseasesR21EY026717 · NEI · MASSACHUSETTS EYE AND EAR INFIRMARY · PI KEMPEN, JOHN H · 2017 to 2018
$495k
Complications of Immunosupression for Eye DiseasesR56EY014943 · NEI · UNIVERSITY OF PENNSYLVANIA · PI KEMPEN, JOHN H · 2009 to 2009
$159k
CLC NIH HHS 75N90021D00009NCCDPHP CDC HHS NU58DP006344NCI NIH HHS HHSN261201800009CNCI NIH HHS HHSN261201800009INCI NIH HHS HHSN261201800015CNCI NIH HHS HHSN261201800015INCI NIH HHS HHSN261201800032CNCI NIH HHS HHSN261201800032INEI NIH HHS R01 EY014943NEI NIH HHS R21 EY026717NEI NIH HHS R56 EY014943NHLBI NIH HHS 75N92021D00009NIEHS NIH HHS 75N96021D00009ORFDO NIH HHS 75N99021D00009
6 · The paper itself

Abstract

Objective: Evaluate the association between cancer incidence and immunosuppressive treatment in patients with ocular inflammatory disease (OID). Methods and analysis: We performed a retrospective cohort study of patients from 10 US OID subspecialty practices. Patients with non-infectious OID were included; HIV-infected patients were excluded. Time-dependent exposure to drug classes (ie, antimetabolites, calcineurin inhibitors, alkylating agents, tumour necrosis factor (TNF) inhibitors) and drugs were evaluated. Cancer incidence was ascertained by linkage to 12 state cancer registries from 1996 to 2015. Cancer incidence was analysed using Cox regression survival analysis, using 0-year, 3-year and 5-year lags after immunosuppression began. Results: The cancer incidence cohort comprised 10 872 individuals at risk of incident cancer and residing in one of the 12 states covered; 812 primary cancers were identified through cancer incidence tracing with median follow-up time of 10 years. Neither TNF inhibitor, antimetabolite, calcineurin inhibitor nor alkylating agent classes were associated with statistically significant increases in cancer incidence adjusting for covariates. We found statistically significant reduced hazards in the systemic inflammatory disease (SID)-including cohort for adalimumab and chlorambucil, increased hazards for tacrolimus and etanercept in the non-SID cohort and reduced hazards for methotrexate in both. Other immunosuppressive drugs were not associated with overall cancer incidence. Conclusions: We found no increased risk of overall or site-specific cancer incidence associated with short-term (non-transplant) therapy with most commonly used immunosuppressive drug classes and many specific drugs. Further research may clarify potentially protective or harmful effects of specific agents that were not consistently associated with reduced or increased cancer incidence. Trial registration number: NCT00116090.

Indexed as

epidemiologyimmunomodulation

Identifiers

PMID39886503
PMCPMC11203086

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.